Mohammad Jahanzeb YOU? Author Swipe

Last 10y

International experts consensus on optimal central vascular access device selection and management for patients with cancer Open

Mohammad Jahanzeb, Ching-Yang Wu, Howard J. Lim, Kei Muro, Lichao Xu , et al. · 2024

Background: In patients with cancer, the choice of an appropriate venous access device is crucial for effective treatment, minimizing complications, and reducing healthcare costs. Key management decisions, such as the timing of device remo…

P2.10-15 Correlation Between Clinical and Health-related Quality-of-Life (HRQoL) Benefits in Patients With ALK+ NSCLC in ALTA-1L Open

Rosario Garcίa‐Campelo, Huamao Mark Lin, M. Pérol, Mohammad Jahanzeb, Annette Szumski , et al. · 2023

Table S2 from Enrichment of PI3K-AKT–mTOR Pathway Activation in Hepatic Metastases from Breast Cancer Open

Mariaelena Pierobon, Corinne Ramos, Shukmei Wong, K. Alex Hodge, Jessica Aldrich , et al. · 2023

Proportion of patients with mutation/activation of the PIK3CA-AKT-mTOR pathway in liver metastases compared to other organ sites and primary tumors of the breast.

Table S1 from Enrichment of PI3K-AKT–mTOR Pathway Activation in Hepatic Metastases from Breast Cancer Open

Mariaelena Pierobon, Corinne Ramos, Shukmei Wong, K. Alex Hodge, Jessica Aldrich , et al. · 2023

Tumor percentage for specimens undergoing exome sequencing.

Data from Enrichment of PI3K-AKT–mTOR Pathway Activation in Hepatic Metastases from Breast Cancer Open

Mariaelena Pierobon, Corinne Ramos, Shukmei Wong, K. Alex Hodge, Jessica Aldrich , et al. · 2023

Purpose: Little is known about the molecular signatures associated with specific metastatic sites in breast cancer. Using comprehensive multi-omic molecular profiling, we assessed whether alterations or activation of the PI3K–AKT–mT…

Table S1 from Enrichment of PI3K-AKT–mTOR Pathway Activation in Hepatic Metastases from Breast Cancer Open

Mariaelena Pierobon, Corinne Ramos, Shukmei Wong, K. Alex Hodge, Jessica Aldrich , et al. · 2023

Tumor percentage for specimens undergoing exome sequencing.

Supplementary Material Legend from Enrichment of PI3K-AKT–mTOR Pathway Activation in Hepatic Metastases from Breast Cancer Open

Mariaelena Pierobon, Corinne Ramos, Shukmei Wong, K. Alex Hodge, Jessica Aldrich , et al. · 2023

Supplementary material legend

Table S3 from Enrichment of PI3K-AKT–mTOR Pathway Activation in Hepatic Metastases from Breast Cancer Open

Mariaelena Pierobon, Corinne Ramos, Shukmei Wong, K. Alex Hodge, Jessica Aldrich , et al. · 2023

AKT S473 distribution based on ER expression measured by IHC for 31 lesions included of the discovery set. ER was measured in a binary scale (Panel A) and in continuous scale using the H-Score (Panel B).

Table S2 from Enrichment of PI3K-AKT–mTOR Pathway Activation in Hepatic Metastases from Breast Cancer Open

Mariaelena Pierobon, Corinne Ramos, Shukmei Wong, K. Alex Hodge, Jessica Aldrich , et al. · 2023

Proportion of patients with mutation/activation of the PIK3CA-AKT-mTOR pathway in liver metastases compared to other organ sites and primary tumors of the breast.

Data from Enrichment of PI3K-AKT–mTOR Pathway Activation in Hepatic Metastases from Breast Cancer Open

Mariaelena Pierobon, Corinne Ramos, Shukmei Wong, K. Alex Hodge, Jessica Aldrich , et al. · 2023

Purpose: Little is known about the molecular signatures associated with specific metastatic sites in breast cancer. Using comprehensive multi-omic molecular profiling, we assessed whether alterations or activation of the PI3K–AKT–mT…

Supplementary Material Legend from Enrichment of PI3K-AKT–mTOR Pathway Activation in Hepatic Metastases from Breast Cancer Open

Mariaelena Pierobon, Corinne Ramos, Shukmei Wong, K. Alex Hodge, Jessica Aldrich , et al. · 2023

Supplementary material legend

Supplemental Tables and Figures from Central Nervous System Metastasis in Patients with HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from SystHERs Open

Sara A. Hurvitz, Joyce O’Shaughnessy, Ginny Mason, Denise A. Yardley, Mohammad Jahanzeb , et al. · 2023

This file includes Supplemental Table 1, Supplemental Table 2, Supplemental Table 3, Supplemental Table 4, Supplemental Table 5, Supplemental Figure 1, Supplemental Figure 2, Supplemental Figure 3, Supplemental Figure 4, and Supplemental F…

Supplementary Data from Baseline Characteristics, Treatment Patterns, and Outcomes in Patients with HER2-Positive Metastatic Breast Cancer by Hormone Receptor Status from SystHERs Open

Melody Cobleigh, Denise A. Yardley, Adam Brufsky, Hope S. Rugo, Sandra M. Swain , et al. · 2023

Supplemental Table 1. Baseline demographics, patient characteristics, and disease characteristics by percentage HR positivity; Supplemental Table 2. HR status concordance rates in primary vs. metastatic tumors in patients with (A) HR-posit…

Figure S1 from Enrichment of PI3K-AKT–mTOR Pathway Activation in Hepatic Metastases from Breast Cancer Open

Mariaelena Pierobon, Corinne Ramos, Shukmei Wong, K. Alex Hodge, Jessica Aldrich , et al. · 2023

Pathway diagram of genes/proteins that were measured for this analyses and found altered across the 32 breast cancer metastases evaluated of the discovery set.

Table S4 from Enrichment of PI3K-AKT–mTOR Pathway Activation in Hepatic Metastases from Breast Cancer Open

Mariaelena Pierobon, Corinne Ramos, Shukmei Wong, K. Alex Hodge, Jessica Aldrich , et al. · 2023

AKT S473 distribution based on ER, HER2 expression measured by IHC in for primary and metastatic lesions included in the validation set.

Table S3 from Enrichment of PI3K-AKT–mTOR Pathway Activation in Hepatic Metastases from Breast Cancer Open

Mariaelena Pierobon, Corinne Ramos, Shukmei Wong, K. Alex Hodge, Jessica Aldrich , et al. · 2023

AKT S473 distribution based on ER expression measured by IHC for 31 lesions included of the discovery set. ER was measured in a binary scale (Panel A) and in continuous scale using the H-Score (Panel B).

Data from Central Nervous System Metastasis in Patients with HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from SystHERs Open

Sara A. Hurvitz, Joyce O’Shaughnessy, Ginny Mason, Denise A. Yardley, Mohammad Jahanzeb , et al. · 2023

Purpose:Patients with HER2-positive metastatic breast cancer (MBC) with central nervous system (CNS) metastasis have a poor prognosis. We report treatments and outcomes in patients with HER2-positive MBC and CNS metastasis from the Systemi…

Figure S1 from Enrichment of PI3K-AKT–mTOR Pathway Activation in Hepatic Metastases from Breast Cancer Open

Mariaelena Pierobon, Corinne Ramos, Shukmei Wong, K. Alex Hodge, Jessica Aldrich , et al. · 2023

Pathway diagram of genes/proteins that were measured for this analyses and found altered across the 32 breast cancer metastases evaluated of the discovery set.

Supplemental Tables and Figures from Central Nervous System Metastasis in Patients with HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from SystHERs Open

Sara A. Hurvitz, Joyce O’Shaughnessy, Ginny Mason, Denise A. Yardley, Mohammad Jahanzeb , et al. · 2023

This file includes Supplemental Table 1, Supplemental Table 2, Supplemental Table 3, Supplemental Table 4, Supplemental Table 5, Supplemental Figure 1, Supplemental Figure 2, Supplemental Figure 3, Supplemental Figure 4, and Supplemental F…

Data from Baseline Characteristics, Treatment Patterns, and Outcomes in Patients with HER2-Positive Metastatic Breast Cancer by Hormone Receptor Status from SystHERs Open

Melody Cobleigh, Denise A. Yardley, Adam Brufsky, Hope S. Rugo, Sandra M. Swain , et al. · 2023

Purpose:We report treatments and outcomes in a contemporary patient population with HER2-positive metastatic breast cancer (MBC) by hormone receptor (HR) status from the Systemic Therapies for HER2-positive Metastatic Breast Cancer Study (…

Figure S2 from Enrichment of PI3K-AKT–mTOR Pathway Activation in Hepatic Metastases from Breast Cancer Open

Mariaelena Pierobon, Corinne Ramos, Shukmei Wong, K. Alex Hodge, Jessica Aldrich , et al. · 2023

Concordance between PIK3CA, AKT, and PTEN mutation status and AKT (S473) and p70S6 (T389) activation.

Figure S2 from Enrichment of PI3K-AKT–mTOR Pathway Activation in Hepatic Metastases from Breast Cancer Open

Mariaelena Pierobon, Corinne Ramos, Shukmei Wong, K. Alex Hodge, Jessica Aldrich , et al. · 2023

Concordance between PIK3CA, AKT, and PTEN mutation status and AKT (S473) and p70S6 (T389) activation.

Table S4 from Enrichment of PI3K-AKT–mTOR Pathway Activation in Hepatic Metastases from Breast Cancer Open

Mariaelena Pierobon, Corinne Ramos, Shukmei Wong, K. Alex Hodge, Jessica Aldrich , et al. · 2023

AKT S473 distribution based on ER, HER2 expression measured by IHC in for primary and metastatic lesions included in the validation set.

Data from Central Nervous System Metastasis in Patients with HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from SystHERs Open

Sara A. Hurvitz, Joyce O’Shaughnessy, Ginny Mason, Denise A. Yardley, Mohammad Jahanzeb , et al. · 2023

Purpose:Patients with HER2-positive metastatic breast cancer (MBC) with central nervous system (CNS) metastasis have a poor prognosis. We report treatments and outcomes in patients with HER2-positive MBC and CNS metastasis from the Systemi…

Supplementary Data from Baseline Characteristics, Treatment Patterns, and Outcomes in Patients with HER2-Positive Metastatic Breast Cancer by Hormone Receptor Status from SystHERs Open

Melody Cobleigh, Denise A. Yardley, Adam Brufsky, Hope S. Rugo, Sandra M. Swain , et al. · 2023

Supplemental Table 1. Baseline demographics, patient characteristics, and disease characteristics by percentage HR positivity; Supplemental Table 2. HR status concordance rates in primary vs. metastatic tumors in patients with (A) HR-posit…

Data from Baseline Characteristics, Treatment Patterns, and Outcomes in Patients with HER2-Positive Metastatic Breast Cancer by Hormone Receptor Status from SystHERs Open

Melody Cobleigh, Denise A. Yardley, Adam Brufsky, Hope S. Rugo, Sandra M. Swain , et al. · 2023

Purpose:We report treatments and outcomes in a contemporary patient population with HER2-positive metastatic breast cancer (MBC) by hormone receptor (HR) status from the Systemic Therapies for HER2-positive Metastatic Breast Cancer Study (…

Real-World Efficacy and Tolerability of Brigatinib in Patients with Non-Small Cell Lung Cancer with Prior ALK-TKIs in the United States Open

Mohammad Jahanzeb, Huamao Mark Lin, Yanyu Wu, Pingkuan Zhang, Magdaliz Gorritz , et al. · 2022

Background Real-world evidence for brigatinib, a next-generation anaplastic lymphoma kinase-tyrosine kinase inhibitor (ALK-TKI) used in ALK-rearranged non-small cell lung cancer, is scarce. This retrospective study evaluated real-world bri…

Author response for "Multi‐omic molecular profiling guide’s efficacious treatment selection in refractory metastatic breast cancer: a prospective phase II clinical trial" Open

Mariaelena Pierobon, Nicholas J. Robert, Donald W. Northfelt, Mohammad Jahanzeb, Shukmei Wong , et al. · 2021

Health-related quality of life in the randomized phase III trial of brigatinib vs crizotinib in advanced ALK inhibitor–naive ALK + non−small cell lung cancer (ALTA-1L) Open

M.R. García Campelo, Huamao Mark Lin, Yanyan Zhu, M. Pérol, Mohammad Jahanzeb , et al. · 2021

Brigatinib significantly delayed time to worsening and prolonged duration of improvement in GHS/QOL versus crizotinib, supported by improvement in functional and symptom scores. These preliminary analyses suggest brigatinib is the first AL…

Reconstructing tumor trajectories during therapy through integration of multiple measurement modalities Open

Jason I. Griffiths, Jinfeng Chen, Onalisa Winblad, Anne O’Dea, Priyanka Sharma , et al. · 2021

Background Accurately determining changes in tumor size during therapy is essential to evaluating response or progression. However, individual imaging methodologies often poorly reflect pathologic response and long-term treatment efficacy …

Fetching topic information...